• Authors: van der Kant, R., Karow-Zwick, A. R., Van Durme, J., Blech, M., Gallardo, R., Seeliger, D., Assfalg, K., Baatsen, P., Compernolle, G., Gils, A., Studts, J. M., Schulz, P., Garidel, P., Schymkowitz, J., Rousseau, F.
  • Year: 2017
  • Journal: J Mol Biol 429 1244-1261
  • Applications: in vitro / DNA / PEIpro
  • Cell type: CHO-3E7
    Description: Chinese hamster ovary cell line expressing a truncated but functional form of EBNA1.


Protein aggregation remains a major area of focus in the production of monoclonal antibodies. Improving the intrinsic properties of antibodies can improve manufacturability, attrition rates, safety, formulation, titers, immunogenicity, and solubility. Here, we explore the potential of predicting and reducing the aggregation propensity of monoclonal antibodies, based on the identification of aggregation-prone regions and their contribution to the thermodynamic stability of the protein. Although aggregation-prone regions are thought to occur in the antigen binding region to drive hydrophobic binding with antigen, we were able to rationally design variants that display a marked decrease in aggregation propensity while retaining antigen binding through the introduction of artificial aggregation gatekeeper residues. The reduction in aggregation propensity was accompanied by an increase in expression titer, showing that reducing protein aggregation is beneficial throughout the development process. The data presented show that this approach can significantly reduce liabilities in novel therapeutic antibodies and proteins, leading to a more efficient path to clinical studies.